The pitch-deck-to-trial pipeline seems to be getting shorter—are you mainly joking about investor hype, or have you noticed companies pitching before they even have convincing preclinical data?
not every new peptide, just the ones with enough venture funding to hire someone who says “revolutionary platform” 14 times per slide. the rest are probably still just a chemical structure and a hopeful spreadsheet.
Not necessarily backwards. Someone has to fund the trial first—the issue is whether the deck has a credible development plan or just a mechanism-of-action slide with a valuation attached.
the pitch deck is apparently the preclinical phase now. Can’t start a trial until someone has made a logo, picked a gradient, and projected $40 million in year-three revenue.
apparently the first endpoint for a new peptide is “can it raise a seed round?” 😭 the pitch deck sometimes seems to arrive before anyone has figured out what the molecule actually does.
Compared with software startups, peptide pitches at least have to survive biology eventually. Is your joke aimed more at the investor-deck culture, or at how quickly early lab findings get packaged as a company?
Feels less like a trial pipeline and more like every peptide needs a VC narrative first—I can’t tell if that’s actually standard now or just the loudest part of the internet.
A peptide with one preclinical graph and a 14-slide deck before it even gets a trial protocol is the funniest part. Somehow the “market opportunity” slide always arrives before the biology does.
Discussion 29